On October 13th, 2021 Defence Therapeutics Inc. ("Defence" or the "Company"), a biotechnology company working on cancer therapeutics and infectious disease vaccines reported strong in vitro results of its AccumTM variants on the recent Enhertu (fam-trastuzumab-deruxtecan-nxki) ADC owned by AstraZeneca and Daiichi Sankyo (Press release, Defence Therapeutics, OCT 13, 2021, View Source [SID1234626239]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Defence has successfully selected and tested 5 AccumTM variants to the T-deruxtecan ADC Therapeutic. The 5 selected Accum-T-deruxtecan increases the potency of T-deruxtecan ADC Therapeutic by approximatively 5-fold on the HER2 positive breast cancer Trastuzumab and TDM1 resistant cell line model named JIMT-1. At concentration of 0.001 ug/ml, T-deruxtecan only induce approximatively 13% of cytotoxicity comparatively to the 5 Accum-T-deruxtecan variants that increase the cytotoxicity by 21-37%.

The 5 selected AccumTM variants will be sent to our collaborator at the HUS Comprehensive Cancer Center in Helsinki, Finland for the optimization of Defence’s Accum-T-deruxtecan ADC Therapeutic.

Defence’s AccumTM platform has been developed and tested in vitro to enhance the intracellular drug delivery on multiple ADCs that are FDA approved or under development. The AccumTM technology platform is very efficient at enhancing intracellular delivery of proteins of pharmacological interests such as ADCs or vaccine antigens.

"The strong results confirmed the expectation of our scientific team that the AccumTM can increase the routing and delivery of the T-deruxtecan to the nucleus and consequently increased more significantly the potency of the ADC. That confirms also and again the strength and optimization of our AccumTM platform in the ADC field of therapeutics against cancer and the solid competitive advantage we have with our AccumTM variants derived from our AccumTM technology platform", says Mr. Sebastien Plouffe, CEO of Defence Therapeutics.

According to Facts and Factors market research report, the Global Breast Cancer Treatment Market size & share revenue is expected to grow from USD 19.24 Billion in 2019 to reach USD 34.06 Billion by 2026, at 8.5% annual CAGR growth during forecast period of 2021-2026.